Vote Scores

Home / Companies / Armata Pharmaceuticals, Inc. / 11 Jun 2026

Meeting · year to 30 June 202639 filers reporting

Armata Pharmaceuticals, Inc.: meeting of 11 Jun 2026

Votes reported on Form N-PX, item by item

39 Form N-PX filers reported votes at the Armata Pharmaceuticals, Inc. meeting of 11 Jun 2026. Their records fall into 4 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.

foragainstabstain, withhold or otheramber tick: the portion cast against management

Items

1

DIRECTOR ELECTIONSIssuer

Director elections

7 nominees; 76.8% of reported votes for; 3 filers withheld from or voted against at least one nominee.

98 vote records from 7 filers. 2 of the 7 filers that marked the item either way voted against management.

71.4% for0.0% against28.6% other28.6% against management7 filers
2

SECTION 14A SAY-ON-PAY VOTESIssuer

Advisory vote on executive pay (say-on-pay)

51 vote records from 39 filers. 0 of the 34 filers that marked the item either way voted against management. 5 filers reported this item without a management mark.

87.2% for0.0% against12.8% other0.0% against management39 filers100.0% for0.0% against0.0% against management1,413,765 reported shares
3

SECTION 14A SAY-ON-PAY VOTESIssuer

Frequency of the say-on-pay vote

one year: 33 filers; not applicable: 2 filers; three years: 1 filer.

53 vote records from 39 filers. 1 of the 34 filers that marked the item either way voted against management. 5 filers reported this item without a management mark.

0.0% for0.0% against100.0% other2.9% against management39 filers0.0% for0.0% against100.0% other0.1% against management1,414,658 reported shares
4

AUDIT-RELATEDIssuer

Audit-related items (auditor ratification)

14 vote records from 7 filers. 0 of the 7 filers that marked the item either way voted against management.

100.0% for0.0% against0.0% against management7 filers100.0% for0.0% against0.0% against management516,876 reported shares

How the largest families voted

Family1. Directors2. Say-on-pay3. Pay-vote frequency4. Auditor
VanguardForForSplit or no voteFor
BlackRock and iSharesForForSplit or no voteFor
FidelityForForSplit or no voteFor
State Street and SPDRNo reportForSplit or no voteNo report
EquitableForForSplit or no voteFor
Charles SchwabNo reportForSplit or no voteNo report
Morgan Stanley, Eaton Vance and CalvertNo reportForSplit or no voteNo report
Goldman SachsNo reportSplit or no voteSplit or no voteNo report
Northern Trust and FlexSharesNo reportForSplit or no voteNo report
Victory CapitalAbstain or withhold *ForSplit or no voteFor
BNY MellonNo reportForSplit or no voteNo report

* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.

Questions

How did large funds vote at the Armata Pharmaceuticals, Inc. meeting?

39 Form N-PX filers reported votes at the meeting of 11 Jun 2026. On say-on-pay, 0 of 34 voted against management (0.0%). The family table lists each of the largest families item by item.

Is this the meeting result?

No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Armata Pharmaceuticals, Inc. on Form 8-K.

Why are director elections shown as counts only?

Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.

Every meeting on file for Armata Pharmaceuticals, Inc.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Armata Pharmaceuticals, Inc. with a meeting date within three days of 11 Jun 2026. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.